- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05269758
Feasibility and Impact of Resistance Training for Sarcopenic Dysphagia
February 28, 2023 updated by: Tina Hansen, PhD, MSc.OT, Hvidovre University Hospital
Feasibility and Impact of an Activity-based Intervention for Strengthening Ingestive Functions in Elders With Sarcopenic Dysphagia: a Multiple-case Study
The purpose of the study is to test and optimize the feasibility of an activity-based resistance training program for patients with sarcopenic dysphagia.
The study is a feasibility study designed as a multiple-case study with quantitative and qualitative data sources related to a number of feasibility outcomes and clinical outcomes during and after the intervention.
Participants are 15 patients> 65 years of age are referred for dysphagia assessment by an Occupational Therapist (patients may be admitted to several different wards (endocrinology, pulmonary medicine, infectious medicine, gastrology).
The intervention is offered during hospitalization and after discharge for a maximum of 12 weeks.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Actual)
11
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Hvidovre, Denmark, 2650
- Hvidovre University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
65 years and older (Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Participants admitted to an acute hospital for medical reasons (endocrinology, pulmonary medicine, infectious medicine, gastrology), and referred for dysphagia assessment by an Occupational Therapist .
Description
Inclusion Criteria:
- Speaks and understand Danish language, and able to provide written informed consent for participation
- Dysphagia verified by a Gugging Swallowing Screen
- Generalized sarcopenia determined by a Danish version of the questionnaire SARC-F
- Sarcopenia of the swallowing mechanism indicated by reduced tongue strength measured with the Iowa Oral Performance Instrument
Exclusion Criteria:
- Dysphagia related to the esophagus
- Psychiatric diagnosis
- Neurodegenerative disease or
- Needs palliative care
- Admitted to hospital from a nursing home.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intervention tolerance
Time Frame: During two therapy sessions per week in 12 weeks
|
Time-series of participants rated level of concern for aspiration on a 100 mm VAS-scale ((left side = no concerns and right side = maximal concerns).
The success criterion is that 80% of the VAS scales are in the area of 'no concerns' for aspiration.
|
During two therapy sessions per week in 12 weeks
|
Adverse effects
Time Frame: During two therapy sessions per week in 12 weeks
|
Any expected and unintended events during the therapy sessions and the self-training are recorded.
|
During two therapy sessions per week in 12 weeks
|
Intervention usefulness
Time Frame: Up to 12 weeks
|
Participant self-report on the subscale 'Value/usefulness' from the Intrinsic Motivation Inventory (IMI).
The subscale covers 7 items to be rated on a 7-point Likert scale (1=Not at all true to 7=very true).
A high score indicate high usability.
|
Up to 12 weeks
|
Acceptability
Time Frame: Up to 12 weeks
|
Semi-structured interviews based on the Theoretical Framework of Acceptability
|
Up to 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Emotional wellbeing and global quality of life
Time Frame: Baseline and up to 12 weeks
|
Two single VAS items using a horizontal line from 0 (worst imaginable emotional well-being / worst imaginable quality of life) to 100 mm (perfect emotional wellbeing /perfect quality of life).
|
Baseline and up to 12 weeks
|
Mealtime performance
Time Frame: Baseline and up to 12 weeks
|
The McGill Ingestive Skills Assessment-version 2 (MISA2).
The total score range from 36-108, where higher score indicate higher performance
|
Baseline and up to 12 weeks
|
Functional oral intake
Time Frame: Baseline and up to 12 weeks
|
Functional Oral Intake Scale (FOIS) with a score range of 1( no oral intake) to 7 (Total oral diet with no restrictions).
|
Baseline and up to 12 weeks
|
Nutritional status
Time Frame: Baseline and up to 12 weeks
|
The modified Mini Nutritional Assessment Scale-Short Form (MNA-SF).
The total score range from 0 to 14, where a score <8 indicates malnutrition, 8-11 indicates risk of malnutrition, and >11 indicates no malnutrition.
|
Baseline and up to 12 weeks
|
Tongue strength and endurance
Time Frame: Baseline and up to 12 weeks
|
Iowa Oral Performance Instrument (IOPI).
|
Baseline and up to 12 weeks
|
Intervention progress _ swallow difficulty
Time Frame: During two therapy sessions per week in 12 weeks.
|
Self-reported swallowing difficulty of saliva, liquid and food (100 mm VAS scale (left side = no difficulties and right side = unable to swallow).
|
During two therapy sessions per week in 12 weeks.
|
Intervention progress_ intensity
Time Frame: During two therapy sessions per week in 12 weeks.
|
Self-perceived effort from 0 (at rest) to 10 (extremely hard).
|
During two therapy sessions per week in 12 weeks.
|
Intervention progress _ Swallow ability
Time Frame: During two therapy sessions per week in 12 weeks.
|
Records on observed number of successful/unsuccessful swallows.
|
During two therapy sessions per week in 12 weeks.
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Demand for the intervention by the target group
Time Frame: Though study completion, an average of three years.
|
Records of recruitment/attrition rates.
|
Though study completion, an average of three years.
|
Intervention functionality
Time Frame: Though study completion, an average of three years.
|
Records of numbers of complete/incomplete therapy sessions.
|
Though study completion, an average of three years.
|
Intervention adaptations
Time Frame: During two therapy sessions per week in 12 weeks.
|
Records on any adaptations (minor or major modifications, addition of new components, or deletions of a component) in the intervention model of the ACT-ING program during therapy.
For any adaptations, 'what', 'how' and 'why' are recorded.
|
During two therapy sessions per week in 12 weeks.
|
Determinants for delivering the ACT-ING program by practitioners
Time Frame: Up to 12 weeks.
|
Semi-structured interview based on the Theoretical Domains Framework
|
Up to 12 weeks.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 1, 2020
Primary Completion (Actual)
January 6, 2023
Study Completion (Actual)
February 28, 2023
Study Registration Dates
First Submitted
February 4, 2022
First Submitted That Met QC Criteria
February 25, 2022
First Posted (Actual)
March 8, 2022
Study Record Updates
Last Update Posted (Actual)
March 2, 2023
Last Update Submitted That Met QC Criteria
February 28, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-19039031
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sarcopenia
-
University of Texas at AustinNot yet recruitingExercise Training and SarcopeniaUnited States
-
Centre Hospitalier Universitaire DijonCompleted
-
Creighton UniversityUniversity of NebraskaRecruiting
-
University Hospital, CaenCompleted
-
University of NottinghamUniversity of OxfordRecruitingMuscle Atrophy | Age-Related SarcopeniaUnited Kingdom
-
Tufts UniversityNational Institute on Aging (NIA)CompletedMuscle Loss | Age-Related SarcopeniaUnited States
-
China Medical University HospitalCompleted
-
King's College LondonCo-sponsor: Guy's and St Thomas' NHS Foundation TrustCompletedFrailty | Sarcopenia | Age-Related SarcopeniaUnited Kingdom
-
Norwegian School of Sport SciencesOslo University HospitalNot yet recruitingHealthy Aging | Testosterone Deficiency | Age-Related Sarcopenia
-
Ningbo Medical Center Lihuili HospitalCompletedHemodialysis Patients With SarcopeniaChina
Clinical Trials on activity-based resistance training of ingestive skills (ACT-ING-program)
-
Hvidovre University HospitalRecruitingDeglutition Disorders | Dysphagia, OropharyngealDenmark
-
Roswell Park Cancer InstituteCompletedInvasive Breast CarcinomaUnited States